Comparing Heyu Biological Technology (OTCMKTS:HYBT) & Zynex (NASDAQ:ZYXI)

Zynex (NASDAQ:ZYXI) and Heyu Biological Technology (OTCMKTS:HYBT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Profitability

This table compares Zynex and Heyu Biological Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zynex	3.12%	14.15%	4.50%
Heyu Biological Technology	-453.55%	-6.43%	-4.43%

Valuation & Earnings

This table compares Zynex and Heyu Biological Technology’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$193.61 million	1.33	$9.73 million	$0.23	35.17
Heyu Biological Technology	$80,000.00	322.65	-$270,000.00	N/A	N/A

Zynex has higher revenue and earnings than Heyu Biological Technology.

Risk & Volatility

Zynex has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Heyu Biological Technology has a beta of -17.74, meaning that its stock price is 1,874% less volatile than the S&P 500.

Institutional & Insider Ownership

29.7% of Zynex shares are held by institutional investors. 52.1% of Zynex shares are held by insiders. Comparatively, 89.2% of Heyu Biological Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Zynex and Heyu Biological Technology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	0	0	2	0	3.00
Heyu Biological Technology	0	0	0	0	N/A

Zynex presently has a consensus price target of $14.00, suggesting a potential upside of 72.41%. Given Zynex’s higher possible upside, equities analysts plainly believe Zynex is more favorable than Heyu Biological Technology.

Summary

Zynex beats Heyu Biological Technology on 9 of the 11 factors compared between the two stocks.

About Zynex

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

About Heyu Biological Technology

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.